Literature DB >> 28108290

Pmp22 mutant allele-specific siRNA alleviates demyelinating neuropathic phenotype in vivo.

Ji-Su Lee1, Eun Hyuk Chang2, Ok Jae Koo3, Dong Hwan Jwa4, Won Min Mo4, Geon Kwak1, Hyo Won Moon4, Hwan Tae Park5, Young Bin Hong6, Byung-Ok Choi7.   

Abstract

Charcot-Marie-Tooth disease (CMT) is a genetic disorder that can be caused by aberrations in >80 genes. CMT has heterogeneous modes of inheritance, including autosomal dominant, autosomal recessive, X-linked dominant, and X-linked recessive. Over 95% of cases are dominantly inherited. In this study, we investigated whether regulation of a mutant allele by an allele-specific small interfering RNA (siRNA) can alleviate the demyelinating neuropathic phenotype of CMT. We designed 19 different allele-specific siRNAs for Trembler J (Tr-J) mice harboring a naturally occurring mutation (Leu16Pro) in Pmp22. Using a luciferase assay, we identified an siRNA that specifically and selectively reduced the expression level of the mutant allele and reversed the low viability of Schwann cells caused by mutant Pmp22 over-expression in vitro. The in vivo efficacy of the allele-specific siRNA was assessed by its intraperitoneal injection to postnatal day 6 of Tr-J mice. Administration of the allele-specific siRNA to Tr-J mice significantly enhanced motor function and muscle volume, as assessed by the rotarod test and magnetic resonance imaging analysis, respectively. Increases in motor nerve conduction velocity and compound muscle action potentials were also observed in the treated mice. In addition, myelination, as evidenced by toluidine blue staining and electron microscopy, was augmented in the sciatic nerves of the mice after allele-specific siRNA treatment. After validating suppression of the Pmp22 mutant allele at the mRNA level in the Schwann cells of Tr-J mice, we observed increased expression levels of myelinating proteins such as myelin basic protein and myelin protein zero. These data indicate that selective suppression of the Pmp22 mutant allele by non-viral delivery of siRNA alleviates the demyelinating neuropathic phenotypes of CMT in vivo, implicating allele-specific siRNA treatment as a potent therapeutic strategy for dominantly inherited peripheral neuropathies. Copyright Â
© 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Charcot-Marie-Tooth disease; Demyelination; Gene therapy; Non-viral delivery; PMP22

Mesh:

Substances:

Year:  2017        PMID: 28108290     DOI: 10.1016/j.nbd.2017.01.006

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  6 in total

1.  A translatable RNAi-driven gene therapy silences PMP22/Pmp22 genes and improves neuropathy in CMT1A mice.

Authors:  Marina Stavrou; Alexia Kagiava; Sarah G Choudury; Matthew J Jennings; Lindsay M Wallace; Allison M Fowler; Amanda Heslegrave; Jan Richter; Christina Tryfonos; Christina Christodoulou; Henrik Zetterberg; Rita Horvath; Scott Q Harper; Kleopas A Kleopa
Journal:  J Clin Invest       Date:  2022-07-01       Impact factor: 19.456

Review 2.  Mechanisms and Treatments in Demyelinating CMT.

Authors:  Vera Fridman; Mario A Saporta
Journal:  Neurotherapeutics       Date:  2021-11-08       Impact factor: 6.088

3.  Squalenoyl siRNA PMP22 nanoparticles are effective in treating mouse models of Charcot-Marie-Tooth disease type 1 A.

Authors:  Suzan Boutary; Marie Caillaud; Mévidette El Madani; Jean-Michel Vallat; Julien Loisel-Duwattez; Alice Rouyer; Laurence Richard; Céline Gracia; Giorgia Urbinati; Didier Desmaële; Andoni Echaniz-Laguna; David Adams; Patrick Couvreur; Michael Schumacher; Charbel Massaad; Liliane Massaad-Massade
Journal:  Commun Biol       Date:  2021-03-09

4.  AAV2/9-mediated silencing of PMP22 prevents the development of pathological features in a rat model of Charcot-Marie-Tooth disease 1 A.

Authors:  Benoit Gautier; Helene Hajjar; Sylvia Soares; Jade Berthelot; Marie Deck; Scarlette Abbou; Graham Campbell; Maria Ceprian; Sergio Gonzalez; Claire-Maëlle Fovet; Vlad Schütza; Antoine Jouvenel; Cyril Rivat; Michel Zerah; Virginie François; Caroline Le Guiner; Patrick Aubourg; Robert Fledrich; Nicolas Tricaud
Journal:  Nat Commun       Date:  2021-04-21       Impact factor: 14.919

5.  Peripheral Myelin Protein 22 Gene Mutations in Charcot-Marie-Tooth Disease Type 1E Patients.

Authors:  Na Young Jung; Hye Mi Kwon; Da Eun Nam; Nasrin Tamanna; Ah Jin Lee; Sang Beom Kim; Byung-Ok Choi; Ki Wha Chung
Journal:  Genes (Basel)       Date:  2022-07-08       Impact factor: 4.141

Review 6.  Emerging Therapies for Charcot-Marie-Tooth Inherited Neuropathies.

Authors:  Marina Stavrou; Irene Sargiannidou; Elena Georgiou; Alexia Kagiava; Kleopas A Kleopa
Journal:  Int J Mol Sci       Date:  2021-06-03       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.